OPDIVO® and YERVOY® - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) - for advanced NSCLC
Both OPDIVO® and YERVOY® are administered for 2 years or until disease progression or unacceptable toxicity. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis, Nephritis and Endocrinopathies.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
OPDIVO® (Nivolumab) IV 3 mg/kg D1 q14 NSS 250 cc 60 minutes
YERVOY® (Ipilimumab) IV 1 mg/kg D1 q42 NSS 250 cc 60 minutes